Qiagen

Decent end to 2024

06/02/25 -"Qiagen’s Q4 24 results aligned with market expectations and slightly exceeded management’s guidance. Most segments demonstrated healthy sales growth. While mid-single-digit growth is ..."

PDF page sample
Pages
64
Language
English
Published on
06/02/25
Download
You may also be interested by these reports :
12/02/26
CZM reported weak Q1 results, with challenges in both ophthalmology and microsurgery. Profitability declined significantly due to FX headwinds, an ...
11/02/26
4Q sales increased 12.1% YoY (18.4% at constant currency) to €7.6bn, mainly driven by strong growth in AI glasses. However, this category continues ...
10/02/26
Philips’ Q4 results exceeded expectations, with comparable sales growth driven by strong performance in Personal Health and healthy contributions ...
06/02/26
Coloplast delivered a weak Q1, with both revenue and adjusted EBIT missing consensus. Organic growth of 6% was in line with expectations, but ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO